Effectiveness and safety of iodopovidone in an experimental pleurodesis model
Autor(a) principal: | |
---|---|
Data de Publicação: | 2013 |
Outros Autores: | , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Clinics |
Texto Completo: | https://www.revistas.usp.br/clinics/article/view/76802 |
Resumo: | OBJECTIVES: Chemical pleurodesis is an important therapeutic tool to control recurrent malignant pleural effusion. Among the various sclerosing agents, iodopovidone is considered effective and safe. However, in a recent study, ocular changes were described after iodopovidone was used in recurrent pneumothorax. The aim of the study was to evaluate the efficacy and morbidity of iodopovidone pleurodesis in an experimental model. METHODS: New Zealand rabbits were submitted to intrapleural injection of iodopovidone at concentrations of 2%, 4% and 10%. Biochemical (lactic dehydrogenase, proteins, triiodothyronine, free thyroxine, urea and creatinine) and immunological (Interleukin-8 [IL-8], VEGF and TGFβ) parameters were measured in the pleural fluid and blood. After 1, 3, 7, 14 and 28 days, groups of animals were euthanized, and macro- (pleura) and microscopic (pleura and retina) analyses were performed. RESULTS: An early pleural inflammatory response with low systemic repercussion was observed without corresponding changes in thyroid or renal function. The higher concentrations (4% and 10%) correlated with greater initial exudation, and maximum pleural thickening was observed after 28 days. No changes were observed in the retinal pigment epithelium of the rabbits. CONCLUSION: Iodopovidone is considered to be an effective and safe sclerosing agent in this animal model. However, its efficacy, tolerance and safety in humans should be further evaluated. |
id |
USP-19_bacfffebe7b8f29dbeb52c91e14d9f7e |
---|---|
oai_identifier_str |
oai:revistas.usp.br:article/76802 |
network_acronym_str |
USP-19 |
network_name_str |
Clinics |
repository_id_str |
|
spelling |
Effectiveness and safety of iodopovidone in an experimental pleurodesis modelOBJECTIVES: Chemical pleurodesis is an important therapeutic tool to control recurrent malignant pleural effusion. Among the various sclerosing agents, iodopovidone is considered effective and safe. However, in a recent study, ocular changes were described after iodopovidone was used in recurrent pneumothorax. The aim of the study was to evaluate the efficacy and morbidity of iodopovidone pleurodesis in an experimental model. METHODS: New Zealand rabbits were submitted to intrapleural injection of iodopovidone at concentrations of 2%, 4% and 10%. Biochemical (lactic dehydrogenase, proteins, triiodothyronine, free thyroxine, urea and creatinine) and immunological (Interleukin-8 [IL-8], VEGF and TGFβ) parameters were measured in the pleural fluid and blood. After 1, 3, 7, 14 and 28 days, groups of animals were euthanized, and macro- (pleura) and microscopic (pleura and retina) analyses were performed. RESULTS: An early pleural inflammatory response with low systemic repercussion was observed without corresponding changes in thyroid or renal function. The higher concentrations (4% and 10%) correlated with greater initial exudation, and maximum pleural thickening was observed after 28 days. No changes were observed in the retinal pigment epithelium of the rabbits. CONCLUSION: Iodopovidone is considered to be an effective and safe sclerosing agent in this animal model. However, its efficacy, tolerance and safety in humans should be further evaluated.Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo2013-04-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://www.revistas.usp.br/clinics/article/view/7680210.1590/clin.v68i4.76802Clinics; Vol. 68 No. 4 (2013); 557-562Clinics; v. 68 n. 4 (2013); 557-562Clinics; Vol. 68 Núm. 4 (2013); 557-5621980-53221807-5932reponame:Clinicsinstname:Universidade de São Paulo (USP)instacron:USPenghttps://www.revistas.usp.br/clinics/article/view/76802/80664Teixeira, Lisete R.Vargas, Francisco S.Puka, JulianaAcencio, Milena M. P.Antonangelo, LeilaTerra, Ricardo M.Damico, Francisco M.Pitta, Fabio G.Marchi, Evaldoinfo:eu-repo/semantics/openAccess2014-03-21T18:32:41Zoai:revistas.usp.br:article/76802Revistahttps://www.revistas.usp.br/clinicsPUBhttps://www.revistas.usp.br/clinics/oai||clinics@hc.fm.usp.br1980-53221807-5932opendoar:2014-03-21T18:32:41Clinics - Universidade de São Paulo (USP)false |
dc.title.none.fl_str_mv |
Effectiveness and safety of iodopovidone in an experimental pleurodesis model |
title |
Effectiveness and safety of iodopovidone in an experimental pleurodesis model |
spellingShingle |
Effectiveness and safety of iodopovidone in an experimental pleurodesis model Teixeira, Lisete R. |
title_short |
Effectiveness and safety of iodopovidone in an experimental pleurodesis model |
title_full |
Effectiveness and safety of iodopovidone in an experimental pleurodesis model |
title_fullStr |
Effectiveness and safety of iodopovidone in an experimental pleurodesis model |
title_full_unstemmed |
Effectiveness and safety of iodopovidone in an experimental pleurodesis model |
title_sort |
Effectiveness and safety of iodopovidone in an experimental pleurodesis model |
author |
Teixeira, Lisete R. |
author_facet |
Teixeira, Lisete R. Vargas, Francisco S. Puka, Juliana Acencio, Milena M. P. Antonangelo, Leila Terra, Ricardo M. Damico, Francisco M. Pitta, Fabio G. Marchi, Evaldo |
author_role |
author |
author2 |
Vargas, Francisco S. Puka, Juliana Acencio, Milena M. P. Antonangelo, Leila Terra, Ricardo M. Damico, Francisco M. Pitta, Fabio G. Marchi, Evaldo |
author2_role |
author author author author author author author author |
dc.contributor.author.fl_str_mv |
Teixeira, Lisete R. Vargas, Francisco S. Puka, Juliana Acencio, Milena M. P. Antonangelo, Leila Terra, Ricardo M. Damico, Francisco M. Pitta, Fabio G. Marchi, Evaldo |
description |
OBJECTIVES: Chemical pleurodesis is an important therapeutic tool to control recurrent malignant pleural effusion. Among the various sclerosing agents, iodopovidone is considered effective and safe. However, in a recent study, ocular changes were described after iodopovidone was used in recurrent pneumothorax. The aim of the study was to evaluate the efficacy and morbidity of iodopovidone pleurodesis in an experimental model. METHODS: New Zealand rabbits were submitted to intrapleural injection of iodopovidone at concentrations of 2%, 4% and 10%. Biochemical (lactic dehydrogenase, proteins, triiodothyronine, free thyroxine, urea and creatinine) and immunological (Interleukin-8 [IL-8], VEGF and TGFβ) parameters were measured in the pleural fluid and blood. After 1, 3, 7, 14 and 28 days, groups of animals were euthanized, and macro- (pleura) and microscopic (pleura and retina) analyses were performed. RESULTS: An early pleural inflammatory response with low systemic repercussion was observed without corresponding changes in thyroid or renal function. The higher concentrations (4% and 10%) correlated with greater initial exudation, and maximum pleural thickening was observed after 28 days. No changes were observed in the retinal pigment epithelium of the rabbits. CONCLUSION: Iodopovidone is considered to be an effective and safe sclerosing agent in this animal model. However, its efficacy, tolerance and safety in humans should be further evaluated. |
publishDate |
2013 |
dc.date.none.fl_str_mv |
2013-04-01 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://www.revistas.usp.br/clinics/article/view/76802 10.1590/clin.v68i4.76802 |
url |
https://www.revistas.usp.br/clinics/article/view/76802 |
identifier_str_mv |
10.1590/clin.v68i4.76802 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
https://www.revistas.usp.br/clinics/article/view/76802/80664 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo |
publisher.none.fl_str_mv |
Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo |
dc.source.none.fl_str_mv |
Clinics; Vol. 68 No. 4 (2013); 557-562 Clinics; v. 68 n. 4 (2013); 557-562 Clinics; Vol. 68 Núm. 4 (2013); 557-562 1980-5322 1807-5932 reponame:Clinics instname:Universidade de São Paulo (USP) instacron:USP |
instname_str |
Universidade de São Paulo (USP) |
instacron_str |
USP |
institution |
USP |
reponame_str |
Clinics |
collection |
Clinics |
repository.name.fl_str_mv |
Clinics - Universidade de São Paulo (USP) |
repository.mail.fl_str_mv |
||clinics@hc.fm.usp.br |
_version_ |
1800222760129003520 |